A Study of Avastin (Bevacizumab) in Patients With Multiple Myeloma

Summary

This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.

Timeline

Start

2006-05

Primary completion

2008-05

Completion

2008-05

Outcome

Outcome not reported

Stopped (Enrollment): “The study was discontinued prematurely by the sponsor due to a lack of recruitment.”

Drugs

Indications